{"id":50861,"date":"2025-12-15T22:16:56","date_gmt":"2025-12-15T14:16:56","guid":{"rendered":"https:\/\/flcube.com\/?p=50861"},"modified":"2025-12-15T22:16:57","modified_gmt":"2025-12-15T14:16:57","slug":"novo-nordisks-wegovy-7-2mg-gets-ema-positive-opinion-for-obesity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50861","title":{"rendered":"Novo Nordisk&#8217;s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity"},"content":{"rendered":"\n<p><strong>Novo Nordisk A\/S<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of <strong>Wegovy (semaglutide 7.2 mg)<\/strong>. The new dose demonstrated an <strong>average weight loss of 20.7% at 72 weeks<\/strong> in people with obesity without diabetes.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-amp-development-updates\">Regulatory &amp; Development Updates<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>European Union<\/strong><\/td><td>CHMP positive opinion for 7.2 mg<\/td><td>Single-dose device application submitted<\/td><\/tr><tr><td><strong>United States<\/strong><\/td><td>Under review; CNPV received<\/td><td>FDA submission: November\u202f2025; 1\u20112 month review expected<\/td><\/tr><tr><td><strong>UK &amp; Others<\/strong><\/td><td>Under review<\/td><td>Multiple regulatory submissions underway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-results-amp-label-expansion\">Clinical Results &amp; Label Expansion<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dose<\/th><th>Weight Loss<\/th><th>Population<\/th><\/tr><\/thead><tbody><tr><td><strong>Wegovy 7.2 mg<\/strong><\/td><td><strong>20.7% average at 72 weeks<\/strong><\/td><td>Obesity without diabetes<\/td><\/tr><tr><td><strong>Wegovy 2.4 mg (EU label)<\/strong><\/td><td>Proven weight management<\/td><td>Adults: BMI \u226530 kg\/m\u00b2 or \u226527 kg\/m\u00b2 with comorbidity; Pediatrics: \u226512 years, BMI \u226595th percentile, &gt;60\u202fkg<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Expanded Label Benefits (EU 2.4 mg):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MACE risk reduction<\/strong> (major adverse cardiovascular events)<\/li>\n\n\n\n<li><strong>HFpEF symptom improvement<\/strong> (heart failure with preserved ejection fraction)<\/li>\n\n\n\n<li><strong>Knee osteoarthritis pain reduction<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Obesity Market<\/strong><\/td><td>$35\u202fbillion (2025)<\/td><td>Projected $60\u202fbillion by 2030<\/td><\/tr><tr><td><strong>Wegovy Peak Sales<\/strong><\/td><td><strong>$15\u201120\u202fbillion<\/strong> (global estimate)<\/td><td>7.2 mg dose expands eligible patient population<\/td><\/tr><tr><td><strong>Competitive Position<\/strong><\/td><td><strong>First GLP\u20111 with 20%+ weight loss<\/strong><\/td><td>Differentiates from Lilly\u2019s tirzepatide (~15\u201120%)<\/td><\/tr><tr><td><strong>Pediatric Market<\/strong><\/td><td>First GLP\u20111 approved for adolescents \u226512 in EU<\/td><td>Expands addressable population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Wegovy\u2019s regulatory approvals, market projections, and label expansions. Actual results may differ due to regulatory delays, competitive responses, or safety profile changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NYSE: NVO) announced that the European Medicines Agency\u2019s Committee for Medicinal Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50863,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[148,860,86,15],"class_list":["post-50861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-novo-nordisk","tag-nyse-nvo","tag-obesity","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk&#039;s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy (semaglutide 7.2 mg). The new dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity without diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50861\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk&#039;s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy (semaglutide 7.2 mg). The new dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity without diabetes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50861\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T14:16:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-15T14:16:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1512.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk&#8217;s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity\",\"datePublished\":\"2025-12-15T14:16:56+00:00\",\"dateModified\":\"2025-12-15T14:16:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1512.webp\",\"keywords\":[\"Novo Nordisk\",\"NYSE: NVO\",\"Obesity\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50861#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50861\",\"name\":\"Novo Nordisk's Wegovy 7.2mg Gets EMA Positive Opinion for Obesity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1512.webp\",\"datePublished\":\"2025-12-15T14:16:56+00:00\",\"dateModified\":\"2025-12-15T14:16:57+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy (semaglutide 7.2 mg). The new dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity without diabetes.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50861\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1512.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1512.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk's Wegovy 7.2mg Gets EMA Positive Opinion for Obesity\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50861#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk&#8217;s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's Wegovy 7.2mg Gets EMA Positive Opinion for Obesity - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy (semaglutide 7.2 mg). The new dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity without diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50861","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk's Wegovy 7.2mg Gets EMA Positive Opinion for Obesity","og_description":"Novo Nordisk A\/S (NYSE: NVO) announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy (semaglutide 7.2 mg). The new dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity without diabetes.","og_url":"https:\/\/flcube.com\/?p=50861","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-15T14:16:56+00:00","article_modified_time":"2025-12-15T14:16:57+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1512.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50861#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50861"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk&#8217;s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity","datePublished":"2025-12-15T14:16:56+00:00","dateModified":"2025-12-15T14:16:57+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50861"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50861#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1512.webp","keywords":["Novo Nordisk","NYSE: NVO","Obesity","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50861#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50861","url":"https:\/\/flcube.com\/?p=50861","name":"Novo Nordisk's Wegovy 7.2mg Gets EMA Positive Opinion for Obesity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50861#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50861#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1512.webp","datePublished":"2025-12-15T14:16:56+00:00","dateModified":"2025-12-15T14:16:57+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) announced that the European Medicines Agency\u2019s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy (semaglutide 7.2 mg). The new dose demonstrated an average weight loss of 20.7% at 72 weeks in people with obesity without diabetes.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50861#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50861"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50861#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1512.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1512.webp","width":1080,"height":608,"caption":"Novo Nordisk's Wegovy 7.2mg Gets EMA Positive Opinion for Obesity"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50861#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk&#8217;s Wegovy 7.2mg Gets EMA Positive Opinion for Obesity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1512.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50861"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50861\/revisions"}],"predecessor-version":[{"id":50864,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50861\/revisions\/50864"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50863"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}